Anaptysbio (ANAB) Accumulated Expenses (2016 - 2026)

Anaptysbio (ANAB) has 11 years of Accumulated Expenses data on file, last reported at $5.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 84.61% year-over-year to $5.5 million; the trailing twelve-month figure through Mar 2026 stood at $5.5 million (down 84.61% YoY), and the FY2025 full-year result was $11.1 million, up 31.31% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $5.5 million, down from $11.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $38.4 million in Q3 2024 and bottomed at $5.5 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $30.2 million (2025), against an average of $24.8 million.
• The widest annual swing landed in 2023, when Accumulated Expenses surged 110.39%; it then tumbled 84.61% in 2026.
• A 5-year view of Accumulated Expenses shows it stood at $21.6 million in 2022, then surged by 43.15% to $31.0 million in 2023, then tumbled by 72.72% to $8.4 million in 2024, then jumped by 31.31% to $11.1 million in 2025, then plunged by 50.12% to $5.5 million in 2026.
• The last three Accumulated Expenses figures came in at $5.5 million (Q1 2026), $11.1 million (Q4 2025), and $33.2 million (Q3 2025), per Business Quant data.

Peer Comparison